A drug called tofacitinib citrate which is classified as a Janus kinase inhibitor and which

prevents the production of an inflammatory mediators called cytokines has been used

successfully to treat patients with a severe type of eczema called atopic dermatitis

characterized by itching and red and cracked skin with a preponderance for the

front of the elbows and back of the knees.

Atopic dermatitis or eczema seems to have a definite genetic predisposition and people

with it are also more prone to asthma and hay fever.

The Janus kinase inhibitor drugs(JAK) are also being proposed as possible treatments

for psoriasis,vitiligo(loss of skin pigment),and a type of hair loss called alopecia

areata. In addition,they are currently being used for rheumatoid arthritis.

Although generally well tolerated, JAK drugs can result in rare opportunistic infections ,

malignancies,and elevated lipids(cholesterol,triglycerides).

 

 

Breaking News 

Disclaimer

The skin and medicine website is intended for educational purposes only and is not intended to treat, cure or diagnose your condition, nor is this information or products or treatments on this site to be used in lieu of consulting your physician or other qualified health care provider.